新しいザヌブルチニブ160mg錠剤を評価するための相対的生物利用性,食品効果,および生物同等性研究:健康なボランティアの2つの第1相試験の結果
Bilal Tariq1, Chester Lin2, Vaibhav Mundra1
1Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA.
Clinical pharmacology in drug development
|September 3, 2025
まとめ
新しいザヌブルチニブ錠剤はカプセルと同等で,全身の曝露も同等です. この新しい錠剤は,食事と併用しても服用でき,錠剤の負荷を減らすことで患者さんの服用習慣を改善する可能性があります.
科学分野:
- 薬理学について
- 臨床薬局
- 薬物開発
背景:
- ザヌブルチニブは,B細胞悪性腫瘍に対する承認されたブルトンチロシンキナーゼ阻害剤です.
- 患者の治療体験を向上させるには,新しい口服用薬の評価が不可欠です.
研究 の 目的:
- 既存のカプセルと比較して,新しいザヌブルチニブ錠剤の相対的な生物利用性と食品効果を評価する.
- ザンブルチニブ錠剤とカプセル製剤の生物同等性を確認する.
主な方法:
- 2つのフェーズ1のランダム化クロスオーバー試験 (N=43とN=58) で,ザヌブルチニブ錠 (160 mg) とカプセル (80 mg) が評価されました.
- 濃度時間曲線下の面積 (AUC) と最大血濃度 (Cmax) を含む,薬理学的なパラメータを測定した.
- ナソガストリック管の投与の可能性について,インビトロ試験で錠剤の分散を評価した.
主要な成果:
- ザヌブルチニブ錠は,空腹状態でのカプセルと比較可能な全身露出量 (AUC) を示した.
- 脂肪が多い食事は,錠剤AUCに最小限の影響を及ぼしたが,Cmaxは増加し,食事に伴いまたは伴わない投与を支えた.
- AUCの生物同等性は確認され,錠剤Cmaxのわずかな増加は臨床的に有意とは考えられない.
結論:
- 新しいザヌブルチニブ錠剤はカプセルに適した代替品であり,生物対価性と好ましい食品効果のプロファイルを示しています.
- 錠剤の組成は,錠剤の負荷を減らし,長期にわたるアデンスを改善するなどの潜在的な利点を提供します.
- in vitro結果は,鼻胃管経由での投与に適していることを示唆している.
さらに関連する動画
関連する概念動画
Bioavailability: Overview
3.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.1K
Factors Influencing Bioavailability: First-Pass Elimination
6.9K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.9K
Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Factors Affecting Drug Biotransformation: Biological
231
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
231
Phase II Reactions: Glucuronidation
767
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
767


